http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
增損五積丸(碑積方)이 사람의 各種 癌細胞株의 成長沮碍에 미치는 效果
李竝求,元秦喜,文錫哉,金東雄,元京淑,文九 한국전통의학연구소 2002 한국전통의학지 Vol.12 No.1
chemosensitivity test of Geungsonojukwhan-Bijukbang was performed on the three different human cancer cell lines originated from liver, cervix and colon tissue, namely Hep 3B, Hela and HCT-15, which have similar doubling times. Semiautomated sulforhodamine B(SRB) assay appears to offer an valuable tool for chemosensitivity of unknown compounds, since it is a simple, valid and inexpensive method of assessing drug monitoring for large samples in a short time. The results obtained in this study were as follows 1. Good correlations were shown from the results of SRB assay and those of clogenetic assay. 2. As a result of exposure to Geungsonojukwhan, the proliferation of Hela cell and Hep 3B cell was slightly decreased in Geungsonojukwhan-Bijukbang(GIP), Geungsonojukwhan-Pejukbang(LUP) and Geungsonojukwhan-Sinjukbang(RTP). 3. As a result of exposure to Geungsonojukwhan, GIP showed better anticancer effect to HCT-15 cell lines than those of LUP and RTP. 4. The extract of Geungsonojukwhan-Bijukbang in 40℃ were more effective in cytotoxic response than those in 100℃. 5. The research showed that the higher concentration the more effective in the inhibition of proliferation of the cancer cell lines, however, the cytotoxic effect of Geungsonojukwhan-Bijukbang in the concentration of 1.60mg/㎖ and 3.20mg/㎖ showed the most effective inhibition rate according to the increase of concentration.
Cisplatin에 의한 뇌세포사멸에서 補中免疫丹의 방어효과
유경태,문석재,원진희,김동웅,이종덕,원경숙,문구 대한동의생리학회,대한동의병리학회 2003 동의생리병리학회지 Vol.17 No.2
This study was designed to investigate the protective effect of Bojungmyunyuk-dan(BJMY-Dan) on the cisplatin-induced cytotoxicity of primary rat astrocytes. BJMY-Dan is an oriental herbal prescription for its ability to recover protectve effects against anti-cancer chemotherapies. After astrocytes were treated cisplafin, MTT assay was performed for cell viability test. To explore the mechanism of cytotoxicity, I used the several measures of apoptosis to determine whether this processes was involved in cisplatin-induced cell damage in astrocytes. AJso, astrocytes were treated with BJMY-Dan and then, followed by the addition of cisplatin. Cisplatin decreased the viability of astrocytes in a dose and time-dependent manner. BJMY-Dan increased the viability of astrocytes treated cisplatin. Astrocytes treated cisplatin were revealed as apoptosis characterized by nuclear staining and flow cytometry. BJMY-Dan protected astrocytes from cisplatin-induced nuclear fragmentation and chromatin condensation. Also, caspase-3 and caspase-9 proteases were activated in astrocytes by cisplatin. BJMY-Dan inhibited the activation of caspase proteases in cisplatin-treated astrocytes. Cleavage of [poly(ADP-ribose) polymerase](PARP) was occurred at 12hr after treatment of cisplatin in astrocytes. BJMY-Dan recovered the cleavage of PARP in cisplatin-treated astrocytes. Also, BJMY-Dan inhibited the activation of pro-apoptotic factor, Bak by cisplatin. Lastly, astrocytes stained with JC-1 and Rhodamine 123 were photographed by fluorescence microscope to visualize changes of mitochondrial membrane permeability transition(MPT) during treatment with cisplatin for 24hr. BJMY-Dan recovered the change of MPT by cisplatn in astrocytes. According to above results, BJMY-Dan may protect astrocytes from cytotoxicity induced by chemotherapeutic agents, including cisplatin.